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Abstract
The protein MSTO1 has been localized to mitochondria and linked
to mitochondrial morphology, but its specific role has remained
unclear. We identified a c.22G > A (p.Val8Met) mutation of MSTO1
in patients with minor physical abnormalities, myopathy, ataxia,
and neurodevelopmental impairments. Lactate stress test and
myopathological results suggest mitochondrial dysfunction. In
patient fibroblasts, MSTO1 mRNA and protein abundance are
decreased, mitochondria display fragmentation, aggregation, and
decreased network continuity and fusion activity. These character-
istics can be reversed by genetic rescue. Short-term silencing of
MSTO1 in HeLa cells reproduced the impairment of mitochondrial
morphology and dynamics observed in the fibroblasts without
damaging bioenergetics. At variance with a previous report, we
find MSTO1 to be localized in the cytoplasmic area with limited
colocalization with mitochondria. MSTO1 interacts with the fusion
machinery as a soluble factor at the cytoplasm-mitochondrial
outer membrane interface. After plasma membrane permeabiliza-
tion, MSTO1 is released from the cells. Thus, an MSTO1 loss-of-
function mutation is associated with a human disorder showing
mitochondrial involvement. MSTO1 likely has a physiologically
relevant role in mitochondrial morphogenesis by supporting mito-
chondrial fusion.
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Introduction
Mitochondria are highly dynamic organelles whose morphology,
distribution, and activity are dependent on fusion and fission (Chan,
2006). Several neurodegenerative diseases such as optic atrophy,
Charcot–Marie–Tooth, Alzheimer’s, Parkinson, and Huntington
disease are associated with alterations of mitochondrial dynamics
(Chan, 2006; Itoh et al, 2013).
MSTO1 (Misato) is an evolutionarily conserved nuclear DNA-
encoded protein showing some structural similarity to eukaryotic
tubulins and prokaryotic FtsZ. Null mutations of the misato in
Drosophila are associated with irregular chromosomal segregation
(Miklos et al, 1997; Gurvitz et al, 2002; Mottier-Pavie et al, 2011).
However, depletion of MSTO1 by siRNA was also linked to mito-
chondrial fragmentation and cell death, and overexpressed EGFP-
Misato was localized in the mitochondria and was shown to induce
aggregation of mitochondria at the perinuclear region and cell death
in HeLa cells (Kimura & Okano, 2007). In this study, MSTO1 was
proposed to contribute to the cell’s health as an outer mitochondrial
membrane (OMM) resident affecting mitochondrial morphology.
However, the mechanism by which MSTO1 supports mitochondrial
morphogenesis and its potential human disease relevance remains
elusive.
Disorders with primary mitochondrial dysfunction are clinically
heterogeneous disorders that can manifest at any age, and can affect
multiple tissues and organs, commonly the most energy demanding
tissues, such as the central nervous system, skeletal and cardiac
muscle, liver, endocrine glands, kidney, and the eyes. Mitochondrial
diseases can result from mutations of genes located in either the
nuclear DNA or the maternally inherited mitochondrial DNA. Until
now, based on the relevant databases (Mitomap, MitoMiner, NCBI,
Nexprot), approximately 300 different mtDNA pathogenic mutations
have been found. The collection of nuclear genes encoding mito-
chondrial proteins is still changing, and only a few hundred
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disease-associated mutations of these genes have been identified.
The minimum prevalence of all mitochondrial disorders is 1:2,000
(Suomalainen, 2015), but with the recent progress in identification
of the mitochondrial proteins and the progress in genetic diagnosis,
the number of human disease-associated mutations is expected to
steeply increase.
In this study, we have identified an MSTO1 mutation in patients
by whole-exome sequencing. This mutation segregated in the
affected family and is absent in the other sequenced cases. Members
of the affected family showed a diverse collection of the following
alterations: severe myopathy, hypoacusis, endocrine dysfunctions,
and psychiatric symptoms. These symptoms and laboratory tests
indicate a possible role for the newly found MSTO1 mutation in the
background of mitochondrial disorders. Therefore, we have investi-
gated mitochondrial dynamics and bioenergetics in both patient-
derived cells and cell lines using genetic rescue and gene silencing,
respectively. Collectively, our studies suggest that MSTO1 is a cyto-
plasmic protein required for mitochondrial fusion and network
formation and its loss likely causes a multisystem disorder.
Results
Clinical data
Patient 1 (I/1) (Fig 1A)
A 53-year-old Hungarian female patient’s symptoms started at the
age of 38 with myalgia, weakness of the small hand muscles, and
cognitive dysfunction. She was born as an immature, small baby
from an overdue pregnancy. Her III digit on the foot was absent.
Her motor and verbal development was delayed. Her bone age was
also delayed. She had joint hyperlaxity and generalized lipomatosis.
Presently, she has hyperthyroidism; mitral and tricuspidal insuffi-
ciency. Neurological examination revealed short stature (150 cm),
micrognathia with small close-set eyes, myopia, myopathic face,
bilateral hypoacusis, moderate atrophy of the small muscles of the
hands and feet, pes varus. She had mild weakness in the distal
muscles of the extremities. Deep tendon reflexes were decreased;
pyramidal tract signs were not present. She had distal type hypaes-
thesia in the limbs. Mild truncal and upper limb ataxia and dysdi-
adochokinesis were present. She had anxiety and depressed mood.
Her brain MRI detected frontal atrophy and enlarged interhemi-
spheric fissure and EMG showed myopathy. CK was in normal
range. The resting serum lactate level was normal, while the lactate
stress test indicated altered aerobic metabolism (resting lactate:
1.7 mmol/l (normal range: 1.0–2.0 mmol/l), after 15 min bicycling
0 min: 6.5 mmol/l, 5 min: 4.8 mmol/l, 15 min: 4.2 mmol/l,
30 min: 3.5 mmol/l (normal if the lactate level after 30 min exercise
is less than twofold of the resting value)). Decreased vitamin D3
was measured (13.0 ng/ml, normal range 23.0–60.0 ng/ml). Using
light microscopy, the myopathological investigations detected
moderate muscle fiber caliber variation. No ragged blue or COX
negative fibers were present. Electron microscopy found increased
number of mitochondria and lipid droplets both in subsarcolemmal
and intermyofibrillar localization. Many mitochondria had rounded
shape; intramitochondrial paracrystalline inclusions were not
present. Glycogen accumulation was also detected in these regions
(Fig 1B).
Patient 2 (II/1)
The 30-year-old daughter of patient 1 (Fig 1A) was born from breech
position. She was resuscitated. She had normal development. From
age 11, episodically inflammatory lipomas occurred on her body. Her
psychiatric symptoms stared at age 15 with depression and hallucina-
tions. Severe undifferentiated type of schizophrenia was diagnosed.
Some years later unilateral hypoacusis developed, and she had severe
episodic ataxic gait repeatedly. Hyperthyreosis, hyperprolactanemia,
and primer amenorrhea were detected as well. Neurological examina-
tion revealed mild weakness in the tibial anterior muscles and distal
type hypaesthesia in the legs. Her CK and resting serum lactate level
was in normal range. This patient did not agree to perform the lactate
stress test. The vitamin D3 level was low (8.6 ng/ml). Her brain MRI
detected pituitary adenoma and mild cerebellar ectopia.
Patient 3 (II/2)
The 24-year-old male patient was born from normal pregnancy. He
had normal motor development. In his childhood, bone develop-
mental problems were suspected based on his laboratory results
(abnormal vitamin D3, calcium, phosphate, and ALP levels). The
social anxiety started in the childhood. Later dyslexia, dysgraphia,
dyscalculia, and learning difficulties were detected. His neurological
examination revealed micrognathia, pectus excavatum, kyphoscol-
iosis, poor fine coordination, and slow psychomotility. CK was
normal. Vitamin D3 was decreased (12.5 ng/ml).
Patient 4 (II/3)
The 20-year-old male patient was born as a hypotonic infant; his
early development was delayed. He had a social anxiety since his
early childhood and learning difficulties. Presently, he has autistic
features with anxiety and impulsive behaviors. He had very long
face, prominent jaw, and laxity of the knee joints. No neurological
signs were found. The vitamin D3 level was low (10.8 ng/ml).
Mutation analysis
Mitochondrial DNA mutation was not found in either blood or skele-
tal muscle samples, and single or multiple mtDNA deletions have
been excluded as well.
Exome capture sequencing generated ~9.4 billion bases of
sequence, and ~9.3 billion bases were then mapped to the target
regions based on SeqCap_EZ_Exome_v3 Kit. 95% of the target
regions had at least 10× coverage. After identification of variants, we
focused only on non-synonymous variants, splice acceptor and
donor site mutations, and short, frame shift coding insertions or
deletions (indel). Using GEM.app software with autosomal dominant
model after filtering out synonymous SNPs, 61 heterozygous vari-
ants remained, including 1 coding indel, 57 missense, 1 splice-site, 2
nonsense mutations. Further narrowing based on protein prediction
scores resulted in 27 variations. We did not find any homozygous or
compound heterozygous rare variants in the 1,015 genes, which
were previously associated by the literature with mitochondrial func-
tion. The narrowing analysis for known mitochondrial genes filtered
out 25 heterozygous (2 nonsense and 23 missense) variants. Among
the rare variant filtering by the autosomal dominant inheritance
model 16 genes were without any known function. Based on the
literature, further seven genes were excluded because these genes
are not linked to CNS involvements or mitochondrial dysfunctions.
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Finally, four missense mutations were validated with Sanger
sequencing. Among them only the c.22 G>A (p.Val8Met) substitu-
tion in MSTO1 gene is segregated in all affected family members and
was present in heterozygous form (Table EV1 and Fig 1C). This
mutation was found in urinary tract and colorectal tumors, as a
somatic mutation (COSM3930426, COSM3930426) (http://cancer.sa
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II/1
MSTO P2
II/2 II/3
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Patient 1 MAGGVREMLTLQLGHFAGFVGAHW 24
Homo sapiens 1 MAGGAREVLTLQLGHFAGFVGAHW 24
Pan troglodytes 1 MAGGAREVLTLQLGHFAGFVGAHW 24
Bos taurus 1 MAGGAREVLTLQLGHFAGFVGAHW 24
Mus musculus 1 MAGGAREVLTLQLGHFAGFVGAHW 24
Rattus norvegicus 1 MAGGAREVLTLQLGHFAGFVGAHW 24
Meleagris gallopavo 1 MAG---EAVTLQLGHYAGCVGAHW 21
Xenopus tropicalis 17 ------EIVTVQLGPFSNCLGAHW 34
Danio rerio 1 MSGACREVVTLQLGHYSNFIGTHW 24
Drosophila melanogaster 5 -----REILTFQFGTYANYVGTHF 23
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Figure 1. Clinical and genetic data of the patient.
A Family tree of the investigated patients. Arrow indicates the proband.
B Electron microscopy sections of the patient muscle biopsy specimen. Increased number of mitochondria both subsarcolemmal and intermyofibrillar, lipid droplets,
and glycogen accumulation (electron microscopy, 30,000×).
C Sequenogram of the suspected pathogenic mutation and the neighboring polymorphism in exon 1 of MSTO1 gene from genomic (upper part) and cDNA (lower part).
Arrow indicates the position of the mutation.
D Taxonomical alignments of the affected MSTO1 protein sequence. Location of the alterations in the patients are shown in bold. The red “M” indicates the amino acid
substitution segregated in all affected family members.
E Normalized mRNA expression level from the patient primary fibroblasts (percentage of the average value of the healthy controls) (mean  SEM).
F MSTO1 Western blotting of the patient and control fibroblast. Left: representative blots; right: normalized protein abundance of the percentage of the average protein
expression levels of the controls (mean  SEM).
Source data are available online for this figure.
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nger.ac.uk); according to the Exome Aggregation Consortium
(ExAC) database (http://exac.broadinstitute.org), the minor allele
frequency is 0.003% (rs762798018), and it was absent in 1000
Genome (http://www.1000genomes.org), NHLBI Exome Sequencing
Project (ESP) (http://evs.gs.washington.edu/EVS/), ClinVar (http://
www.ncbi.nlm.nih.gov/clinvar), dbGAP (http://www.ncbi.nlm.
nih.gov/gap), and EGA (http://www.ebi.ac.uk/ega) databases.
Connection with any clinical phenotype has not been described, yet.
The mutated part of MSTO1 protein sequence is highly conserved in
mammals (Fig 1D). This alteration was confirmed by cDNA sequenc-
ing from fibroblast as well (Fig 1C). Other alterations ofMSTO1 gene
were excluded by Sanger sequencing of the total coding sequence
from genomic DNA and cDNA sequencing from patient derivate
fibroblasts (MSTO P1, II/1 and MSTO P2, I/2). The copy number
alteration was also excluded by real-time PCR methodology.
In the patient-derived primary fibroblast culture, the MSTO1
mRNA and protein expression were significantly decreased (MSTO
P1 and MSTO P2) compared with the average values of three
controls (Fig 1E and F). The MSTO1 mRNA expression was
42.0  3.0% in MSTO P1 and 36.3  4.7% in MSTO P2 (Fig 1E),
while the protein abundance was 71.4  2.3% in MSTO P1 and
61.0  1.6% in MSTO P2 (Fig 1F). The other two affected family
members did not agree to the skin biopsy.
In silico analysis
Based on the prediction of the InterPro domain software, MSTO1
protein has 2 tubulin/Ftz-like GTPase domains. The prediction of
GTP binding residues in the protein sequence by GTP-binder appli-
cation (Chauhan et al, 2010) found seven possible GTP binding
sites in the first (aa 16-21; 23-24; 30; 62-63; 73-74; 76-77; and 81)
tubulin/Ftz GTPase domain (Fig EV1A).
The protein alignments between MSTO1 and the known mito-
chondrial fusion proteins detected some similarities in a 12 amino
acid span with the OMM fusion proteins, MFN1 and MFN2
(Fig EV1B). These amino acids are located in the second tubulin/
Ftz, GTPase domain of the MSTO1 protein and are highly conserved
in mammals (Fig EV1C). To determine the significance of the simi-
larity between MSTO1 and MFN1, BLAST alignments using
randomly scrambled versions of each protein were performed with
the default parameters for multiple sequence alignment (word size
3, BLOSUM62 matrix). Out of 100 alignments MFN1 and scrambled
MSTO1s and 100 alignments of MSTO1 and scrambled MFN1s, 17
(8.5%) aligned segments with an equal or higher bit-score were
found. Thus, the homology is not statistically significant in and of
itself, though we would note the strong conservation across species
of the acidic amino acids in MSTO1 and mitofusins. No similarity
was found between MSTO1 and the inner mitochondrial membrane
(IMM) fusion protein, OPA1.
Mitochondrial morphology in primary fibroblasts
Mitochondrial morphology was visualized in fibroblasts obtained
from I/2: MSTO1 Patient 1 (P1) and II/1: MSTO1 Patient 2 (P2), the
2 family members who agreed to undergo skin biopsy, and from 3
individuals serving as controls (Ctrl 1, 2, and 3), expressing mito-
chondrial matrix-targeted DsRed1 (mtDsRed). The cells with various
mitochondrial morphology (Fig EV2A) were quantified as a
percentage of the total number of transfected cells (≥ 20 cells per
experiment, n = 5 independent experiments). More cells with aggre-
gated mitochondria were counted in MSTO1 patient fibroblasts than
in the controls (P1: 37.8%; P2: 33.3%; Ctrl average: 11.7  0.4%).
In patient fibroblasts, the percentage of cells with fragmented and
partially fragmented mitochondria was also increased (P1, partially
fragmented: 46.7%, fragmented: 17.3; P2: partly fragmented:
48.8%, fragmented: 8.5%; Ctrl average: partly fragmented:
25.1  1%, fragmented: 0  0%) (Fig EV2A–C).
Mitochondrial continuity in primary fibroblasts
To evaluate whether the distinct mitochondrial morphology in
patient and control fibroblasts can result from different levels of
interorganellar continuity and fusion events, the cells were co-trans-
fected with cDNA encoding mtDsRed1 and mitochondrial matrix-
targeted photoactivatable GFP (mtPA-GFP). Using confocal micro-
scopy, time series of fluorescence images were recorded and 25 lm2
square-shaped areas were illuminated by a pulsed laser to photoacti-
vate mtPA-GFP (Eisner et al, 2014; Weaver et al, 2014), which is a
soluble protein that shows rapid diffusion (Partikian et al, 1998).
Mitochondrial matrix continuity and connectivity is unveiled by the
diffusion of the photoactivated mtPA-GFP to the regions outside the
2P illuminated area. Image time series shows that mtPA-GFP diffu-
sion was slower in P1 than in the age-matched Ctrl3 fibroblasts
(Fig 2A). To quantify connectivity, the time course of the ratio of
FmtPA-GFP and FmtDsRed was calculated for the region of photoactiva-
tion (RPA) in both P1 and P2 and in the three controls (Fig 2B). At
500 s, the lesser decay of the fluorescence ratio in the RPA indicates
a decrease in the combined activity of mitochondrial network
formation, mitochondrial fusion, and mitochondrial movements in
the MSTO1 patient cells (Fig 2B).
Mitochondrial fusion dynamics in primary fibroblasts
To validate fusion events, reciprocal spreading of mtPA-GFP and
mtDsRed among mitochondria that were not continuous at the time
of mtPA-GFP photoactivation was sought (Fig 3A). The fusion events
were quantitatively analyzed by the progression of the distribution of
mtPA-GFP fluorescence between the images collected in the first 8
min after photoactivation. The result of manual counting indicates
less mitochondrial fusion activity in the MSTO1 patient fibroblasts
(Fig 3B). The total fusion numbers were decreased significantly
in the patient fibroblasts (P1: 4.01  0.13 fusion/run; P2:
3.50  0.12 fusion/run; Ctrl average: 6.39  0.24 fusion/run)
(Fig 3B). In a previous study, we have quantified the effect of two
different ADOA-associated OPA1 mutations on the mitochondrial
fusion activity using the same manual counting method used in the
present study (Eisner et al, 2014). G300E point mutation in the
GTPase domain and D58 deletion of the GTPase domain caused
60–70% decrease in the fusion activity, whereas the present MSTO1
mutations induced an approximately 40% decrease in fusion activity.
However, we have also studied an ADOA-associated OPA1 mutation
(c.984) that caused a lesser decrease in the fusion activity (30%)
than the present MSTO1 mutations. Thus, the MSTO1-associated
fusion decrease is in the range of the OPA1-associated ones.
Fusion activity was also quantified by an algorithm that
calculates the loss of the green-only pixels during the
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post-photoactivation period. This unbiased determination showed
that the average half-time of the GFP-only pixel loss was increased
significantly in the MSTO1 fibroblasts (P1: 1,914  305 s; P2:
1,817  312 s; Ctrl average: 713  105 s). Thus, results obtained
by two different approaches show that mitochondrial fusion activity
is suppressed in the MSTO1-deficient patient cells.
The average duration of individual fusion events was similar in
both MSTO1 fibroblasts and in age-matched controls (P1: 133  7 s;
P2: 133  7 s; Ctrl average: 117  6 s) (Fig 3C). Furthermore, the
distribution of different fusion types in terms of rapid reversal
(Fig 3D) and orientations (Fig 3E) did not show any alterations in
MSTO1 fibroblasts as compared with controls. In addition, the abun-
dance of the main fusion (MFN1, MFN2, and OPA1) and fission
(DRP1) proteins was unaltered in MSTO1 fibroblasts (Fig 3F).
MSTO1 overexpression restores mitochondrial fusion dynamics in
MSTO1 patient fibroblasts
To test whether normal mitochondrial fusion phenotype can be
restored by MSTO1 overexpression in MSTO1 patient fibroblasts, a
bicistronic expression vector for MSTO1 and mtDsRed was created
(mtDsRed1-T2A-MSTO1). Upon transfection of the P2 fibroblasts
MSTO P1
mtDsRed1
mtPA-GFP
Ctrl3
20μm
0s 24s 40s 500s
Photoactivation
* *
Ctrl1 Ctrl2 Ctrl3 MSTO
P1
MSTO
P2
A
B
Figure 2. Mitochondrial continuity in primary fibroblasts.
A Image time series showing a representative fibroblast cell before and after 2P photoactivation of mtPA-GFP (white squares): 0 s (pre-activation), 24 s (immediately
after photoactivation), 40 s, and 500 s.
B The time course of the ratio of FmtPA-GFP to FmtDsRed for the region of photoactivation (RPA) (left); the decay of the fluorescence ratio in the RPA at 500 s (right) (number
of imaged cells: Ctrl1 N = 94; Ctrl2 N = 45; Ctrl3 N = 87; MSTO P1 N = 84; MSTO P2 N = 130 from minimum three experiments per each cells). Stars indicate the
significant differences (Student’s t-test: Ctrl average vs. MSTO P1 *P = 1.44 × 109, Ctrl average vs. MSTO P2 *P = 1.52 × 1012; one-way ANOVA: P = 0.00815)
(mean  SEM).
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Figure 3.
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with this vector, the abundance of MSTO1 protein was greatly
increased as compared with pcDNA-transfected cells (186%,
Fig 4A). Only a hardly noticeable band appeared at the expected
molecular weight of the mtDsRed1-T2A-MSTO1 complex, indicating
that it was effectively processed to give rise to separated MSTO1
and mtDsRed proteins (Fig 4A).
To evaluate fusion dynamics, the fibroblasts were then co-trans-
fected with mtPA-GFP and either mtDsRed1-T2A-MSTO1 or
mtDsRed and pcDNA. In the microscopy studies, the MSTO1 overex-
pressing cells were identified based on the mtDsRed fluorescence
(images in Fig 4B). The spreading of mtPA-GFP fluorescence from
the areas of photoactivation was accelerated in the MSTO1 overex-
pressing cells (Fig 4B). The decrease in the fluorescence ratio at the
RPA was significantly greater after MSTO1 transfection and was
similar to the average value of the three controls (MSTO1-trans-
fected P2 cells: 0.37  0.02; only mtDsRed-transfected MSTO P2
cells: 0.2  0.01; average of controls: 0.35  0.02 s) (Fig 4C). The
average half-time of the GFP-only pixel loss was decreased signifi-
cantly in the MSTO1 overexpressed cells (pcDNA-transfected cells:
1,714  300 s, MSTO1-transfected cells: 954  137 s, npcDNA = 34;
nMSTO1 = 36; P = 0.00343). The MSTO1 gene delivery normalized
the fusion numbers as well (Fig 4D). After MSTO1 transfection, the
average fusion number was 5.2  0.4/run (0.65  0.0/min), while
in the mtDsRed-transfected cells 3.52  0.3/run (0.44  0.02/min)
fusion events were counted (Fig 4D). As a reference, the average
fusion numbers of control fibroblasts were 6.4  0.1/run,
0.8  0.0/min (Fig 4D). However, MSTO1 overexpression did not
alter the reversibility (Fig 4E), duration (Fig 4F), and orientation
(Fig 4G) of the fusion events.
MSTO1 silencing inhibits mitochondrial fusion in HeLa cells
Next, in order to avoid the complexities and high variability of the
cells derived from different individuals, the possible contribution of
MSTO1 to fusion dynamics was assessed in HeLa cells. Gene silenc-
ing was performed with either MSTO1-targeting or scrambled
siRNA. Immunoblotting confirmed the MSTO1 depletion (Fig 5A).
Following 72-h silencing, the protein amount of MSTO1 was
49  3% compared to the scrambled siRNA control. In the MSTO1-
silenced cells, the expression of MFN1, MFN2, OPA1, and DRP1
was not significantly changed (Fig 5A).
Mitochondrial fusion dynamics was evaluated upon co-transfec-
tion of the siRNA-treated cells with mtPA-GFP and mtDsRed. The
siMSTO1 cells showed increased mitochondrial fragmentation
(Fig EV2D and E) and relatively slow spreading of mtPA-GFP from
the photoactivation areas (Fig 5B and C). Applying the fusion quan-
tification algorithm, the average half-time of the GFP-only pixel loss,
which inversely correlates with mitochondrial fusion activities, was
increased significantly in the MSTO1-silenced cells (MSTO1-silenced
cells: 505  101 s, scramble siRNA-silenced cells: 247  20 s,
nScr = 45; nMSTO1 = 58; P < 0.00001). Consistent with this, the manu-
ally counted fusion number also decreased in the siMSTO1 condition
(Fig 5D). After MSTO1 siRNA transfection, the average fusion number
was 10.9  0.1/run, while in the scramble siRNA-transfected cells
20.1  0.5/run fusion events were counted (Fig 5D). The average
duration of the fusion events slightly increased upon MSTO1 targeting
(Fig 5E), whereas the distribution of the different fusion types (Fig 5F)
and the orientation of the fusion events (Fig 5G) were not changed.
Mitochondrial motility is maintained in patient fibroblasts
We have previously shown that mitochondrial fusion can be controlled
indirectly through changes in mitochondrial motility (Liu et al, 2009;
Twig et al, 2010). Therefore, mitochondrial motility was quantified in
the MSTO1 patient fibroblasts as well as in the controls in side-by-side
comparisons (Fig EV3). The results show that P2 had similar mito-
chondrial movement activity to Ctrl1 and more than Ctrl2 (P = 0.97
and P = 0.0063, respectively, Kruskal–Wallis one-way ANOVA,
Dunn’s multiple comparison test), and P1 was similar to Ctrl3 in terms
of mitochondrial motility (P = 0.10, Mann–Whitney rank sum test).
Thus, the decrease in mitochondrial fusion is not secondary to a
decrease in mitochondrial motility in the MSTO1-deficient patient cells.
Mitochondrial membrane potential, Ca2+ uptake, and respiration
after MSTO1 silencing
To determine whether the effect of MSTO1 silencing on mitochon-
drial fusion might be secondary to an effect on mitochondrial bioen-
ergetics, the mitochondrial membrane potential (DΨm) and Ca
2+
uptake were determined. The resting DΨm and the DΨm loss evoked
by Ca2+ additions were similar in both MSTO1- and scramble
siRNA-silenced cells (Fig 6A). The resting “cytoplasmic” [Ca2+] and
◀ Figure 3. Mitochondrial fusion events in primary fibroblast.A Representative example is shown out of 2,200 events. During photoactivation of mtPA-GFP, mtDsRed is photobleached, allowing detection of the mixing of each
fluorescent protein after mitochondrial fusion. Mitochondria shown in the white box undergo an end-to-end fusion event at 272 s. During the event, mitochondrion
#1 donates fluorescent mtPA-GFP to mitochondrion #2 (acceptor). At the same time, the green acceptor mitochondrion donates fluorescent mtDsRed to
mitochondrion #1. Arrows show the location of the fusion, abrupt, and complementary inter-mitochondrial transfer of the fluorescent proteins. The graphs on the
right show the average mtDsRed1 and mtPA-GFP fluorescence intensities of mitochondrion 1 and mitochondrion 2 before and after fusion event. The white box
indicates two mitochondria before and after fusion.
B Rates of fusion events in primary fibroblasts. Stars indicate the significant differences (Student’s t-test: Ctrl average vs. MSTO P1 *P = 9.6 × 1021, Ctrl average vs.
MSTO P2 *P = 5.3 × 1031; one-way ANOVA: P < 0.00001) (mean  SEM).
C Average duration of fusion events which were followed by fission during the 8-min recording time (mean  SEM).
D Distribution of transient and complete type fusion events.
E Orientation characteristics of fusion events in different fibroblasts (mean  SEM).
F Western blot of the main fusion and fission proteins. Left: representative blots; right: quantified protein abundances in MSTO cells relative to the control cell average
(mean  SEM).
Data information: (B–E) Number of fusions: Ctrl1 N = 599; Ctrl2 N = 292; Ctrl3 N = 551; MSTO P1 N = 299; MSTO P2 N = 459; number of imaged cells: Ctrl1 N = 94; Ctrl2
N = 45; Ctrl3 N = 87; MSTO P1 N = 84; MSTO P2 N = 130 from minimum three experiments per each cells.
Source data are available online for this figure.
ª 2017 The Authors EMBO Molecular Medicine
Aniko Gal et al Linking of MSTO1 to myopathy and ataxia EMBO Molecular Medicine
7
Published online: May 29, 2017 
pcDNA
Ctrl
av.
*
*
MSTO1
Prohibitin
55kDa
30kDa
80kDa
pc
DN
A
MS
TO
1
Photoactivation
40s
pcD
NA
MS
TO
1
Ctrl
av.
pcD
NA
MS
TO
1
Ctrl
av.
pcD
NA
MS
TO
1
A B
Ctrl
av.
pcD
NA
MS
TO
1
Side by side undetermined (%)
End to side transient (%)
End to end complete (%)
Side by side complete (%)
End to side complete (%)
End to end transient (%)
Side by side transient (%)
End to side undetermined (%)
End to end undetermined(%)
29.1 ± 3.1
1.5 ± 0.1
3.2 ± 0.1
23.1 ± 1.1
1.6 ± 0.3
10.2 ± 0.7
47.3 ± 1.3
2.4 ± 0.4
19.1 ± 1.4
48.5 ± 1.1
2.7 ± 0.4
11.2 ± 0.6
0.8 ± 0.4 1.1 ± 0.1
0 ± 0 0 ± 0
2.4 ± 1.4 1.6 ± 0.2
pcDNA MSTO1
25.9 ± 0.7
4.2 ± 1.0
9.7 ± 1.9
37 ± 3.1
5.7 ± 0.7
15.1 ± 1.0
1.5 ± 0.6
0.4 ± 0.1
1.8 ± 0.7
Ctrl av.
20μm0s
mtDsRed1
mtPA-GFP
24s 40s 500s
MSTO1
C
F
D E
G
MSTO-T2A-
mtDsRed1
mtPA-GFP
Figure 4. MSTO1 overexpression in MSTO1 patient fibroblasts.
A Representative Western blot of MSTO1 protein expression after mtDsRed1-T2A-MSTO1 vector delivery (representative of three experiments).
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Source data are available online for this figure.
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the transients caused by CaCl2 boluses were also similar in the
MSTO- and scrambled siRNA-treated cells (Fig 6B).
Respiration function measurements showed that MSTO silencing
was without major effect on basal (Fig 6C) or leak-dependent JO2,
but led to a slight but significant lowering of the maximal electron
transport chain activity (Fig 6C) as determined by injecting the
chemical uncoupler FCCP.
Thus, DΨm generation, mitochondrial Ca
2+ accumulation and
basal respiration do not seem to be affected by short-term MSTO1
depletion, indicating that suppression of mitochondrial fusion is not
secondary to a change in mitochondrial bioenergetics.
MSTO1 protein is mainly localized in the cytoplasmic area and
shows partial colocalization with the mitochondria
In HeLa cells, overexpression of either MSTO1-Myc or mtDsRed1-
T2A-MSTO1 caused an increase in MSTO1 protein amount (465 and
542%, respectively, compared to that in the pcDNA-transfected
cells, Fig 7A). Again, the 80 kDa band representing the uncleaved
mtDsRed1-T2A-MSTO1 complex was faint (Fig 7A).
To test the subcellular distribution of MSTO1, immunostaining
was performed. HeLa cells transfected with mtDsRed1-T2A-MSTO1
vector were stained with anti-MSTO1 antibody 24 h after transfection.
MSTO1 did not show colocalization with the mitochondria; rather,
intense MSTO1 staining was present in the whole cytoplasmic area
(Fig 7B). To further investigate the localization of MSTO1 protein,
HeLa cells were co-transfected with OMM-targeted GFP (OMP25-GFP)
and MSTO-cMyc vectors. 24 h after transfection, the coverslips were
divided into two groups. One group was permeabilized with digi-
tonin (30 lg/ml) before fixation, while the other group was just fixed.
Both the intact and permeabilized cells were stained with anti-MSTO1
or anti-cMyc antibodies. In the intact cells, the MSTO1/Myc signal
and mitochondrial targeted OMP25-GFP colocalization was approx.
30% (MSTO1 staining: 29  2.7%; c-Myc staining: 33.1  2.1%)
(Fig 7C and D). In the permeabilized cells, most of the MSTO1/c-Myc
immunostaining disappeared, and for the remaining signal, the
colocalization was around 50% (MSTO1 staining: 56  1.2%; c-Myc
staining: 48.2  3.1%) (Fig 7C lower images; and Fig 7E).
To complement these results, endogenousMSTO1 protein abundance
was assessed by immunoblotting in both total cell lysate and mitochon-
dria isolated from HeLa cells. When normalized to the amount of the
mitochondrial loading control, prohibitin, the MSTO1 protein amount
was relatively low, only 35% in themitochondrial fraction (Fig 7F).
MSTO1 protein is soluble
Permeabilization of the plasma membrane resulted in almost
complete loss of the immunofluorescence, whereas the mitochon-
drial markers stayed (Fig 7C), indicating that MSTO1 cannot be an
integral or firmly associated mitochondrial protein. Then, it became
important to determine how this protein could interact with the
mitochondrial fusion proteins, which are transmembrane compo-
nents of the OMM or IMM. Therefore, we compared the release
upon plasma membrane permeabilization of MSTO1 to other cellu-
lar proteins (Fig 8A). After plasma membrane permeabilization, in
both the MSTO1-transfected and non-transfected HeLa cells, the
MSTO1 protein is promptly and almost completely released into the
cytoplasmic fraction. In MSTO1 transfected cells after 140 s more
than 60% of MSTO1 protein was released into the cytoplasmicfrac-
tion, while in the non-transfected cells MSTO1 release was even
higher, approximately 88% (Fig 8B). For comparison, we tested the
release of proteins with known localization. Hexokinase II, known
to be loosely bound to the OMM (Chiara et al, 2008), showed less
and slower release than MSTO1 in both conditions (Fig 8B). The
a-tubulin, a soluble cytosolic protein, showed a very similar release
pattern to MSTO1 (Fig 8B). After saponin treatment, in the control
and MSTO1 primary fibroblast cells, similar protein releases were
found.
Mitochondrial intermembrane space proteins represented by
cytochrome c were not released following digitonin or saponin treat-
ments, since the OMM is more resistant to these detergents than the
plasma membrane. However, cytochrome c redistributed to the
cytoplasmic fraction upon tBid (pro-apoptotic Bcl2 protein) addition
(Willis et al, 2007). Lastly, permeabilized cells were exposed to
limited proteolysis with trypsin (100 lg/ml), followed by addition of
soybean trypsin inhibitor (250 lg/ml) (Fig 8). After trypsin treat-
ment, the MSTO, like hexokinase or a-tubulin, disappeared from
both the cytoplasmic and membrane fractions, which further indi-
cated that MSTO1 is localized out of the mitochondria and it can be
loosely bound to the OMM.
Discussion
In this report, we described the first identified human disease-
associated variation of MSTO1 gene in a patient with multisystemic
clinical phenotype. Furthermore, we demonstrated that MSTO1 has
◀ Figure 5. MSTO1 silencing in HeLa cells.A Protein expression of MSTO1 and the main fusion and fission proteins after MSTO1 silencing. Top: representative blots; bottom: normalized protein abundance of the
percentage of the average protein expression levels of the scramble siRNA-treated cells (N = 3) (mean  SEM).
B Image time series showing a representative MSTO1- and scramble siRNA-silenced HeLa cell before and after 2P photoactivation of mtPA-GFP (white squares) as in Fig 2A.
C The time course of the ratio of FmtPA-GFP to FmtDsRed for the region of photoactivation (RPA) (left); the decay of the fluorescence ratio in the RPA at 500 s (right). Stars
indicate the significant differences (Student’s t-test: *P = 5.4 × 104, one-way ANOVA: P = 0.03678) (mean  SEM).
D Rates of fusion events in silenced HeLa cells. Stars indicate the significant differences (Student’s t-test: *P = 7.15 × 1019, one-way ANOVA: P < 0.00001)
(mean  SEM).
E Average duration of fusion events which were followed by fission during the 8-min recording time. Stars indicate the significant differences (Student’s t-test:
*P = 3.67 × 104, one-way ANOVA: P = 0.00052) (mean  SEM).
F Distribution of transient and complete type fusion events.
G Orientation characteristics of fusion events in silenced and control HeLa cells (mean  SEM).
Data information: (C–G) Number of fusions: MSTO1 siRNA N = 386; Scr. siRNA N = 563; number of imaged cells: MSTO1 siRNA N = 54; Scr. siRNA N = 50; from three
experiments.
Source data are available online for this figure.
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Figure 6. Mitochondrial membrane potential and mitochondrial Ca2+ uptake after MSTO1 silencing.
A DΨm measured using TMRE in suspensions of permeabilized HeLa cells. Increase in fluorescence after each CaCl2 pulse indicates depolarization. Left inset shows
resting DΨm as initial TMRE fluorescence normalized to the fluorescence attained after complete depolarization by uncoupler (5 lM FCCP). Left graphs shows the
DΨm loss evoked by Ca
2+ pulses (4 and 3 pairs of scrambled and MSTO siRNA-silenced cells per measurement from two independent experiments). Arrows indicate
the CaCl2 additions (20 lM each) (mean  SEM).
B Clearance of Ca2+ by mitochondria. The cells were challenged by repetitive CaCl2 pulses (20 lM each). Ca
2+ uptake is shown in the representative traces by the decay
of the [Ca2+] increases evoked by each CaCl2 addition (arrows). Left inset shows the mean resting “cytoplasmic” Ca
2+ concentrations, the left graph shows
mitochondrial Ca2+ uptake after each Ca2+ pulse (4 and 3 pairs of scrambled and MSTO siRNA-silenced cells per measurement from two independent experiments)
(mean  SEM).
C JO2 was measured using the Seahorse XF24 analyzer and calculated by subtracting the O2 consumption rates measured prior to injecting the complex III inhibitor
antimycin A (1 lM) from the rate measured after antimycin addition. Basal JO2 refers to the JO2 in cells exposed only to DMEM + substrates. Maximal JO2 refers to
the JO2 after injecting the chemical uncoupler FCCP (250 nM). P-value was calculated using Student’s t-test (P = 0.01). n = 5 different passages per siRNA treatment
(mean  SEM).
Source data are available online for this figure.
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a role in mitochondrial morphogenesis and quality control by
supporting mitochondrial fusion. MSTO1 likely interacts with the
mitochondrial fusion machinery as a soluble factor at the cyto-
plasm–OMM interface.
Sequencing of DNA isolated from the blood (whole exome and
Sanger sequencing) assumed that Val8Met mutation in the MSTO1
gene is responsible for the clinical symptoms in the present family.
The cDNA sequencing confirmed the heterozygous V8M, while in
the genomic DNA no exon loss or multiplication was found in this
gene. Thus, the Hungarian patients seem to have one impaired and
one normal MSTO1 allele, which result in a partial decrease in
MSTO1 mRNA and protein levels. Based on combination of several
criteria, no other known pathogenic mutation is segregated in this
family, but we cannot exclude that partial loss of MSTO1 comes
together with some other factors to cause the patients clinical
picture. Notably, several mitochondria-associated protein distur-
bances (e.g., POLG1, RRM2B, OPA1, MFN2) can be inherited in both
autosomal dominant and recessive manner. Based on previous
observation, the autosomal recessive forms usually associated with
severe, early-onset phenotypes, while in the autosomal dominant
forms linked to milder, adult-onset manifestations (Tyynismaa et al,
2009). Loss-of-function mutations are usually associated with a
◀ Figure 7. Subcellular localization of MSTO1 protein.A Representative Western blot of MSTO1 protein expression after both MSTO1-Myc and mtDsRed1-T2A-MSTO1 gene delivery compared to the pcDNA-transfected cell lysate.
B Subcellular distribution of MSTO1, immunofluorescence visualization was performed with anti-MSTO1 antibody in HeLa cells, which were transfected with
mtDsRed1-T2A-MSTO1 vector 24 h before fixation.
C Localization of MSTO1 protein after 24-h cotransfection with an OMM-targeted GFP (OMP25-GFP) and MSTO-cMyc vectors. The intact (upper part) and permeabilized
(lower part) cells were immunostained with anti-MSTO1 or anti-cMyc antibodies.
D Percentage of MSTO1 colocalization with the mitochondria in intact cells (imaged cells N = 30) (mean  SEM).
E Percentage of MSTO1 colocalization with the mitochondria in permeabilized cells (imaged cells N = 30) (mean  SEM).
F Comparative Western blotting of the MSTO1 expression in total cell lysate and isolated mitochondria fraction in HeLa cells.
Source data are available online for this figure.
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lower amount of the expressed proteins, but depending on its mono-
or biallelic features, the remaining protein level could be different.
For example in the case of OPA1, the autosomal dominant muta-
tions are associated with reduced OPA1 expression (Bonifert et al,
2014), while for the recessive form almost absent protein expression
was found (Spiegel et al, 2016).
Human Misato (MSTO1) was described as an evolutionarily
conserved OMM protein, and it has been implicated in the control of
mitochondrial morphology (Miklos et al, 1997; Gurvitz et al, 2002;
Kimura & Okano, 2007). Our experiments extended this observation
by demonstrating that a decrease in MSTO1 protein in patient
fibroblasts as well as in HeLa cells upon MSTO1 acute silencing was
associated with a decrease in mitochondrial fusion activity specifi-
cally (Figs 2–5). The cause–effect relationship between MSTO1
decrease and fusion inhibition was validated by genetic rescue stud-
ies in the patient fibroblasts (Fig 4). Since the decrease in mitochon-
drial fusion was observed upon 72-h silencing, it unlikely results
from a complex adaptation process. Furthermore, we have shown
that at the same time point, no impairment in DΨm or Ca
2+ handling
or basal respiration was noticeable (Fig 6). Thus, fusion inhibition
is not secondary to an impairment of bioenergetics when MSTO1 is
decreased.
In both fusion and fission, the key factors are the large GTPase
enzymes belonging to the large dynamin superfamily; fusion is
mainly regulated by MFN1, MFN2, and OPA1 (Meeusen et al, 2006;
Song et al, 2009), while fission requires mainly DRP1 (Otera et al,
2010; Loson et al, 2013). However, the protein expression of these
proteins was unaltered in MSTO1 fibroblasts (Fig 3F) as well as in
HeLa cells after MSTO1 silencing (Fig 5A).
MSTO1 protein was originally described as an OMM protein; it
was co-localized with cytochrome c and MitoTracker Orange in
HeLa cells (Kimura & Okano, 2007), and thus, it could be an OMM
fusion mediating factor. However, in our experiments, both overex-
pressed (Fig 7) and endogenous (Fig 8) MSTO1 showed cytoplasmic
localization. Since the majority of endogenous MSTO1 was promptly
released upon plasma membrane permeabilization with a small frac-
tion remaining associated with membranes (Fig 8), including the
mitochondria (Fig 7), MSTO1 likely is a soluble cytoplasmic protein
that might interact with OMM components. Thus, MSTO1 might
serve as a cytoplasmic regulator of the OMM fusion machinery.
Interestingly, partial depletion of MSTO1 is sufficient to impair
fusion (Figs 1 and 5), indicating that MSTO1 might be quantitatively
required for normal mitochondrial fusion activity. However,
because of the lack of direct evidence for an interaction of MSTO1
with a fusion protein, we cannot completely exclude the possibility
that the decrease in MSTO1 induces a generic cellular stress
response. The main argument against this mechanism is that many
aspects of cell and mitochondrial function, including motility and
bioenergetics remained unaltered in the MSTO1-deficient cells. In
any case, further mechanistic studies will be needed to determine
the exact mechanism of the fusion supporting role of MSTO1.
Mitochondrial fusion is central for the maintenance of mtDNA
and function (Ono et al, 2001; Chan, 2006; Chen et al, 2010). It
is sensible that short-term depletion of MSTO1 did not impair
bioenergetics but on the long run in the patients, MSTO1 deple-
tion is expected to cause some impairment in mitochondrial
function. Notably, recent results indicate that impaired trafficking
of functional mitochondria can also cause neuronal and other
tissue’s dysfunction (Nguyen et al, 2014) and mitochondrial
movements are affected by the fusion dynamics (Liu et al, 2009).
However, MSTO1 also has an involvement in cell division that
might be also relevant for some congenital malformations of the
proband. DML1 and Misato might be co-opted into a role in
mtDNA inheritance in yeast, and into a cell division-related mech-
anism in flies. The mutations of DML1 or Misato could inhibit
kinetochore-driven microtubules growth, associated with a strong
mitotic defect; and it has an additional function in the partition-
ing of mitochondrial organelle itself, or in segregation of chromo-
somes (Miklos et al, 1997; Gurvitz et al, 2002; Mottier-Pavie et al,
2011).
In conclusion, our findings indicate that MSTO1 has a role in
mitochondrial morphogenesis and maintenance by specifically
supporting mitochondrial fusion. In contrast to previous findings,
MSTO1 likely interacts with the mitochondrial fusion machinery as
a soluble factor at the cytoplasm–OMM interface. Since a loss-of-
function mutation in MSTO1 is associated with impaired mitochon-
drial dynamics and several symptoms characteristic to mitochon-
drial disease patients, MSTO1 might be a factor in diseases that
have a mitochondrial component.
Materials and Methods
Patient selection and clinical investigations
The patients and controls were collected from the NEPSY Biobank
of the Institute of Genomic Medicine and Rare Disorders, Semmel-
weis University (Molnar & Bencsik, 2006). Written informed
consent was obtained from each individual before sample collec-
tion and molecular genetic testing. The study was approved by
the National Ethical Committee (37/2014 TUKEB). Molecular
genetic analysis was performed for diagnostic purposes in all
investigated patients.
Detailed neurological, cardiology, psychiatric examinations, and
laboratory investigations were performed. Skeletal muscle biopsy
was obtained for light and electron microscopic examination using
standard routine staining. Electroneurography and electromyogra-
phy were performed by standard techniques (Dantech Keypoint,
Denmark).
Molecular genetic studies
DNA was extracted from blood and skeletal muscle using QIAamp
DNA blood and tissue kits, according to the instructions of manufac-
turer (QIAGEN, Hilden, Germany).
The total coding region of mtDNA was screened by Sanger
sequencing using ABI Prism 3500 DNA Sequencer (Applied Biosys-
tems, Foster City, USA); the obtained sequences were compared
with the mitomap databases using NCBI’s Blast application,
while mtDNA deletion was investigated with long PCRs using
Phusion High-Fidelity DNA Polymerase (Finnzyme, Vanta,
Finland).
Exome Capture was performed in two steps according to the
manufacturer’s protocol. Genomic DNA library preparation was
performed by using TruSeq DNA Sample Prep Kit v2-Set A (Illu-
mina), followed by NimbleGen SeqCap EZ Human Exome Library
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v3.0 Kit exome enrichment (Roche). First pre-capture genomic
library was prepared using 1 lg of highly purified genomic DNA.
Crude pre-captured genomic library was analyzed by Agilent 2100
Bioanalyzer 1000 DNA chip to assess library quality. Next, during
exome enrichment step, individual pre-captured libraries were
hybridized to biotinylated NimbleGen SeqCap EZ Human Exome
Library for 68–70 h at 47°C. Hybridized libraries were captured by
magnetic Dynabeads MyOne Streptavidin C1 (Thermo Fisher
Scientific). Streptavidin beads were washed, and the captured
DNA was eluted. Eluted DNA was PCR amplified by 18 cycles.
Crude target-captured libraries were gel purified on 2% E-Gel (Life
Technologies) and cleaned up with QIAquick Gel Extraction Kit
(QIAgen, Hilden, Germany). Target-captured, gel-purified libraries
were analyzed by Agilent 2100 Bioanalyzer 1000 DNA chip to
assess libraries quality. The final library concentration was deter-
mined by manual integration of molecular profile by Agilent 2100
Bioanalyzer 1000 DNA chip. Illumina adaptor-specific qPCR was
also performed for each library to measure the library template
concentration containing adaptor sequences on both ends which
will subsequently form clusters on the Illumina flow cell. All library
pools were sequenced on the HiScanSQ Illumina sequencing
platform, using 2 × 95-bp pair-end sequencing protocol, with an
extra 9-bp index sequencing run. Final exome-captured sequencing
libraries were diluted to 10 nM. Reads were filtered according to
the Q30 standard. 95-bp paired-reads were aligned to the human
reference genome (hg19). The alignment was performed using
Burrows–Wheeler aligner (BWA) software. For variation calling,
Samtools software was used (Li et al, 2009; Li, 2011). After identifi-
cation of variants, we focused only on non-synonymous variants,
splice acceptor and donor site mutations, and short, frame shift
coding insertions or deletions (indel) using Genomes Management
Application (GEM.app) software (Department of Human Genetics,
University of Miami Health System, and Miami, FL, USA).
The WES filtering procedure was the following: GATK
(QUAL) > 50, GQ > 40, RD > 4 quality scores; autosomal dominant
inheritance; only the missense, nonsense, indels, and splice-site rare
variants with MAF < 0.01 were selected. All SNVs higher than three
occurrences in GEMapp were excluded.
For crosschecking, the mitochondrial genetic alterations were
investigated by targeted screening for both autosomal dominant and
recessive inheritance performed in genes, which is responsible for
mitochondrial function. The rare variants were filtered out based on
mitochondrial gene function and disease association used a gene
list, which was created by UNIPROT, NextProt, MitoMiner, and
NCBI databases.
As large-scale genomic data are not available from the Hungarian
population, a mutation with low minor allele frequency may be
population specific. Finally, we prioritized mutations based on
consequence. Exonic frameshift and stop mutations were considered
as damaging. Missense mutations were prioritized, which was based
on the protein prediction score annotations given by ANNOVAR
(Wang et al, 2010). Further narrowing was based on protein predic-
tion scores (Polyphen2 score > 0.5, Mutation taster: disease caus-
ing, SIFT < 0.1, PHASTCONS > 0.5; GERP > 3). Using ACMG
guideline (Richards et al, 2015), the pathogenic and likely patho-
genic variants were confirmed by Sanger sequencing. After identifi-
cation of candidate alterations, the segregation analysis was
performed in all affected family members.
For the validation of the exome capture result COL5A1 Exon 3,
total coding region of MSTO1 from genomic and cDNA, RELN Exon
62, RYR2 Exon 16, were analyzed with bidirectional Sanger sequenc-
ing (the primers listed in Table EV2). The obtained sequences were
compared with the human reference genome (ENST00000371817,
NM_000093.4; ENST00000245564, NM_018116.3; ENST00000343529,
NM_173054.2; ENST00000366574, NM_001035.2) using NCBI’s
Blast application.
The analysis of copy number variation of all exons of MSTO1
gene was performed by quantitative real-time RT–PCR with SYBG
methodology in the real-time PCR StepOnePlus system according
the manufacturer’s instructions (Life Technology). For quan-
tification, the ddCt method was used.
RNA isolation and RT–PCR
Total cellular RNA was isolated using by RNeasy Plus Mini Kit,
according to the instructions of manufacturer (QIAgen, Hilden,
Germany). cDNA was synthesized by high Sensitive cDNA reverse
transcriptase kit (Life Technology) according to the manufacturer’s
instructions. For measuring mRNA level, RT–PCR products were
analyzed by quantitative real-time RT–PCR with TaqMan Gene
Expression Assays of MSTO1 genes (Hs01094406_g1), and GAPDH
(Hs02758991_g1) as endogenous control (Life Technology). All
PCRs were performed in the real-time PCR StepOnePlus system. For
quantification of gene expression level, the ddCt method was used.
Creation of a Mito-DsRed1-T2A-MSTO1 construct
Human MSTO1-Myc was purchased from OriGene (clone
RC200136). To create the mtDsRed1-T2A-MSTO1 construct, first the
sequences of the mtDsRed1 (from the pDsRed1-Mito plasmid,
Clontech) and the human MSTO1 (from the cDNA clone RC200136,
OriGene) were cloned into the pEGFP-N1 plasmid (Clontech) using
the NheI and NotI restriction sites. Next, the sequence of the viral
T2A peptide was inserted between Mito-DsRed1 and MSTO1 result-
ing the cleavage of the single mRNA-coded polypeptide chain
into two pieces during translation (PMID: 22357943). Transfection
was performed using Lipofectamine 2000 (Life Technologies) with
0.7–4 lg of plasmid DNA in serum-free culture medium for 4 h.
Cell lines, cultures, and transfections with siRNA and
plasmid DNA
Fibroblasts were generated from a 6-mm skin punch biopsy taken
under local anesthetic of healthy control individuals (Ctrl1: 35-year-
old male, Ctrl2: 25-year-old female, Ctrl3: 57-year-old male) and
patients carrying a c.22 G>A, p.Val8Met mutation in MSTO1 gene
(MSTO P1, MSTO P2). Cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM), with 4.5 g/l glucose supplemented with
10% fetal bovine serum, 2 mM glutamate, 100 units/ml penicillin/
streptomycin (all from GIBCO, Life Technology), and 110 mg/l
pyruvate (Sigma). All cells were grown at 37°C in a humidified 5%
CO2 incubator. HeLa cells (ATCC) were grown in the above-
described medium without pyruvate.
Before silencing, the cells were plated in antibiotic-free medium,
and the samples were silenced in serum-free culture medium with
MSTO1-specific (s30301, Life Technologies) or scrambled siRNAs
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(Silencer Negative Control #1 siRNA, Life Technologies) (100 nM),
using Oligofectamine (Life Technologies) for 72 h. The efficacy of
silencing was verified with Western blotting. For evaluation of mito-
chondrial morphology and fusion dynamics, the cells were trans-
fected with mtDsRed1 or mtDsRed1-T2A-MSTO1 and mtPA-GFP
plasmid DNAs 24 h before the experiment.
Western blotting
For Western blotting, 40 lg of proteins was loaded into each lane of
a 12% SDS–PAGE and electrophoretically transferred to nitrocellu-
lose filters. Membranes were blocked with blocking buffer (LI-COR
Biosciences), followed by overnight incubation with primary anti-
bodies (Table EV3). Bound antibodies were visualized with IRDye
800 secondary antibodies (LI-COR Biosciences). Quantification of
protein abundance was done by ImageJ software and abundance,
and the relevant bands were normalized to loading controls
(mtHSP70 or prohibitin).
Mitochondria preparation
The cells were trypsinized, then trypsin was neutralized with 2%
BSA, and the cells were washed with Na-HEPES–EGTA. The pellet
was resuspended in a hyposmotic intracellular medium (24 mM KCl,
0.2 mM KH2PO4, 2 mM NaCl, 4 mM HEPES–Tris, 200 lM EGTA,
1 lg/ml of antipain, leupeptin, and pepstatin, 5 mM MgCl2, 100 lM
PMSF) and centrifuged at 1,000 × g. The supernatant was homoge-
nized with cell cracker (18 nm clearance, 15×), and the isoosmolarity
was restored by addition 125 mM sucrose, 120 mM KCl, 1 mM
KH2PO4, 10 mM NaCl, 20 mM HEPES–Tris, 200 lM EGTA, 100 lM
PMSF before centrifugation at 1,000 × g. The supernatant was centri-
fuged at 10,000 × g, and the final pellet (mitochondrial fraction) was
resuspended in protein lysis buffer (RIPA, 1 lg/ml antipain, leupeptin,
and pepstatin, and 100 lMPMSF). All steps were performed at 4°C.
Immunocytochemistry
The adherent cells were fixed with 3% paraformaldehyde in fixation
buffer at 37°C and were immunostained with the anti-MSTO1
(OriGene) or anti-cMyc (Santa Cruz Biotechnology) primary antibod-
ies. The secondary antibodies were labeled with Alexa-488 and Alexa-
546 (Thermo Fisher Scientific). After staining, the coverslips were
post-fixed with 3% paraformaldehyde. In some cases, the cells were
permeabilized before the immunostaining. The cells were washed with
prewarmed (37°C) Na-HEPES–EGTA and permeabilized with 30 lg/ml
digitonin in ICM (120 mM KCl, 10 mM NaCl, 1 mM KH2PO4, 20 mM
Tris-HEPES, pH 7.2, 1 lg/ml antipain, leupeptin, and pepstatin,
0.4 mM KOH, and 2 lM thapsigargin). Image acquisition (512 × 512
pixels) was performed using 488 nm and 561 nm laser lines of an
LSM780 confocal laser-scanning microscope [63×/1.4 NA or 40×/1.4
NA, PlanApo (Carl Zeiss)]. Image analysis was done using either
Spectralyzer (custom designed) or ImageJ software. The percentage of
colocalization was calculated with an ImageJ macro application.
Live cell imaging
Imaging was performed as previously described (Eisner et al, 2014;
Weaver et al, 2014). Briefly, cells were incubated in a 0.25% BSA
containing extracellular medium (ECM) consisting of 121 mM NaCl,
5 mM NaHCO3, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4,
2 mM CaCl2, 10 mM glucose, and 10 mM Na-HEPES, pH 7.4, at
37°C. Recordings of mtPA-GFP and mtDsRed (512 × 512 pixels)
were performed using 488 and 561 nm laser lines at 0.25 /s data
acquisition frequency using the LSM780 microscope. To photoacti-
vate PA-GFP in 2P mode, a pulsed laser system (760 nm, Chame-
leon; Coherent, Inc.) was applied. Image analysis was done using
either Spectralyzer or Zen2010.
Analysis of mitochondrial matrix continuity
Mitochondrial matrix continuity was evaluated by two different
approaches. Spreading of PA-GFP from the area of photoactivation
was evaluated by masking the 5 × 5 lm areas and quantifying the
time-dependent decay in the fluorescence intensity. The images
were thresholded to reach a 0.1% noise-to-signal ratio. Then, the
pixels of the photoactivated areas were subtracted and the PA-GFP-
positive pixels were counted. Image analysis was performed in Spec-
tralyzer imaging software or in Zen2010. Only cells with the same
number of photoactivated areas and no focus loss were compared.
Analysis of GFP-only pixel loss
Automated fusion analysis was accomplished by tracking the area
of GFP-only fluorescence after the simultaneous photoactivation/
photobleaching of PA-GFP and DsRed/RFP. Briefly, in ImageJ, a
rough region of interest was drawn around the entire cell and the
period after photoactivation selected; after “despeckle” filtering, a
single threshold was set for each image series (PA-GFP and RFP)
using the Otsu method. The thresholded RFP series was subtracted
from the GFP to yield the GFP-only areas. The number of green-only
pixels over time was fit by a single exponential (y = ae-bx), and the
time constant (b) (or half-time ln(2)/b) of the exponential decay
was used as the measure of fusion. This measure was verified to
correlate with the number of fusions by manual counting in record-
ings of H9c2 cells (R2 = 0.698, P < 0.0001, n = 31).
Fluorometric measurements of mitochondrial membrane
potential and Ca2+ uptake
The cells (1.6 mg/ml) were suspended in an ICM supplemented
with 2 mM MgATP, 1 mM malate, 1 mM pyruvate, 2 lM thapsi-
gargin, 1 lM FuraFF/FA (TEFLabs), and 2 lM TMRE (Invitrogen).
The extramitochondrial Ca2+ concentration was measured using
FuraFF, whereas the deltapsi was assessed with TMRE. Fluores-
cence was monitored in a multiwavelength excitation/dual wave-
length emission fluorimeter (DeltaRAM; Photon Technology
International). FuraFF and TMRE fluorescence were recorded simul-
taneously using 340–380 nm excitation and 500 nm emission, and
545 nm excitation and 580 nm emission, respectively. Calibration of
the FuraFF signal in terms of lM [Ca2+] was carried out at the end
of each measurement by adding 2 mM CaCl2, followed by 10 mM
EGTA/Tris, pH 8.5. TMRE time courses were normalized to the fluo-
rescence obtained, in the fully depolarized condition upon addition
of an uncoupler, 5 lM FCCP.
To monitor dynamically the MSTO1 protein distribution, the
plasma membrane was permeabilized in suspensions of HeLa cells
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and human fibroblasts. The HeLa cells were effectively permeabi-
lized with digitonin (30 lg/ml), while the primary fibroblast
resisted to digitonin up to 60 lg/ml, but undergone plasma
membrane permeabilization when exposed to saponin (40 lg/ml).
The amount of digitonin and saponin required was determined by
trypan blue uptake (> 95% of the cells). The samples were continu-
ally stirred in a fluorometer cuvette. At specific time points, the
samples were centrifuged at 10,000 × g to separate the membrane
proteins (pellet) from the cytoplasmic fraction (supernatant). After
immunoblotting of the membrane and cytosolic fractions, the
protein abundances were normalized to total cellular protein.
Measurement of respiratory function
HeLa cells were treated with siRNA against MSTO, or scrambled
control siRNA, for 72 h, as already described. The siRNA against
MSTO resulted in a ~50% (48%  9%, mean  SEM) knockdown
of MSTO protein. To perform mitochondrial O2 consumption rate
(JO2) experiments using the Seahorse XF24 analyzer, cells were
seeded into custom plates at 28,000/well the day before the experi-
ment and cultured overnight. To measure JO2, culture media was
replaced by assay media (DMEM plus 25 mM glucose and 4 mM
glutamine as substrates). Cells were then incubated at 37°C, zero
CO2 for 45 min; then, the experiment was started. JO2 measure-
ments comprised repeated cycles of a 2-min mix, a 2-min wait, and
a 2-min measurement. To measure maximal leak-dependent JO2,
oligomycin (2.5 lg/ml; ATP synthase inhibitor) was injected. To
measure maximal electron transport chain activity under the
prevailing substrate conditions, the chemical uncoupler FCCP
(250 nM) was injected. This [FCCP] represents the optimal [FCCP]
based on studies in which these cells were exposed to different
[FCCP]. To measure non-mitochondrial O2 consumption rate, anti-
mycin A (1 lM; complex III inhibitor) was injected. Mitochondrial
O2 consumption (i.e., JO2) was calculated as the rate prior to anti-
mycin minus the rate post-antimycin injection. At the conclusion of
each experiment, protein was lysed in situ and total protein was
measured by the BCA method. JO2 data were normalized by total
protein/well.
Statistics
The data are shown as the mean  SEM of cells from at least three
independent cultures unless it is specified differently. Significance of
differences was calculated by one-way ANOVA analysis or Student’s
t-test.
Expanded View for this article is available online.
Acknowledgements
We are grateful to the patients and their clinicians and healthy volunteers for
providing samples. Thanks to Stephan Züchner for access to GEM.app soft-
ware; to Heidi McBride and Richard J. Youle for reagents, Gyorgy Csordas,
David M. Booth, Melanie Paillard, Valentina Debattisti, Tunde Golenar, and
Gyorgy Bathori for helpful discussions; and to Gyorgyi Bathori, Marianna
Marko, and Monika Sary for their technical help. This study was supported by
the Hungarian Brain Research Program (KTIA_13_NAP-A-III/6 to V.A-V.) and a
Schizo2010 Consortium grant to M.M.J., an HAESF Senior Leadership Program
Fellowship to A.G., and an NIH grant (DK51525) to G.H.
Author contributions
AG, PB, TG, AH, and LN performed the genetic analysis. MJM supervised all the
genetic work, diagnosed the family, and performed the clinical examinations.
AG performed all the cell biology studies with the guidance of SN and SKJ. ELS
designed and carried out the respiratory function measurements. DW created
software for image analysis and PV generated new reagents. GH designed and
supervised the cell biology studies. AG, MJM, and GH wrote the manuscript. All
the authors critically revised the manuscript for intellectual content.
Conflict of interest
The authors declare that they have no conflict of interest.
References
Bonifert T, Karle KN, Tonagel F, Batra M, Wilhelm C, Theurer Y, Schoenfeld C,
Kluba T, Kamenisch Y, Carelli V et al (2014) Pure and syndromic optic
atrophy explained by deep intronic OPA1 mutations and an intralocus
modifier. Brain 137: 2164 – 2177
Chan DC (2006) Mitochondria: dynamic organelles in disease, aging, and
development. Cell 125: 1241 – 1252
Chauhan JS, Mishra NK, Raghava GP (2010) Prediction of GTP interacting
residues, dipeptides and tripeptides in a protein from its evolutionary
information. BMC Bioinformatics 11: 301
Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM, Chan DC
(2010) Mitochondrial fusion is required for mtDNA stability in skeletal
muscle and tolerance of mtDNA mutations. Cell 141: 280 – 289
Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, Sollott
SJ, Forte M, Bernardi P, Rasola A (2008) Hexokinase II detachment from
mitochondria triggers apoptosis through the permeability transition pore
independent of voltage-dependent anion channels. PLoS ONE 3: e1852
Eisner V, Lenaers G, Hajnoczky G (2014) Mitochondrial fusion is frequent in
skeletal muscle and supports excitation-contraction coupling. J Cell Biol
205: 179 – 195
Gurvitz A, Hartig A, Ruis H, Hamilton B, de Couet HG (2002) Preliminary
characterisation of DML1, an essential Saccharomyces cerevisiae gene
related to misato of Drosophila melanogaster. FEMS Yeast Res 2: 123 – 135
The paper explained
Problem
Genetic impairments of mitochondria-associated proteins are poten-
tial contributors in a range of human disorders, but validation of their
variations and determination of their specific functions is difficult.
Results
This work reveals the first dominant mutation in MSTO1 associated
with multisystemic disease in a Hungarian family. Furthermore, the
role of MSTO1 in shaping of mitochondria via regulation of mitochon-
drial fusion is directly demonstrated. At variance with previous work,
MSTO1 is shown to be a soluble cytoplasmic protein that can interact
with the fusion proteins of the outer mitochondrial membrane.
Impact
Thanks to a multidisciplinary collaboration among clinicians, geneti-
cists, and cell biologists, MSTO1 is found to be a new disease-asso-
ciated gene responsible for a rare mitochondrial multisystemic
disorder.
ª 2017 The Authors EMBO Molecular Medicine
Aniko Gal et al Linking of MSTO1 to myopathy and ataxia EMBO Molecular Medicine
17
Published online: May 29, 2017 
Itoh K, Nakamura K, Iijima M, Sesaki H (2013) Mitochondrial dynamics in
neurodegeneration. Trends Cell Biol 23: 64 – 71
Kimura M, Okano Y (2007) Human Misato regulates mitochondrial
distribution and morphology. Exp Cell Res 313: 1393 – 1404
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis
G, Durbin R (2009) The sequence alignment/Map format and SAMtools.
Bioinformatics 25: 2078 – 2079
Li H (2011) A statistical framework for SNP calling, mutation discovery,
association mapping and population genetical parameter estimation from
sequencing data. Bioinformatics 27: 2987 – 2993
Liu X, Weaver D, Shirihai O, Hajnoczky G (2009) Mitochondrial ‘kiss-and-run’:
interplay between mitochondrial motility and fusion-fission dynamics.
EMBO J 28: 3074 – 3089
Loson OC, Song Z, Chen H, Chan DC (2013) Fis1, Mff, MiD49, and MiD51mediate
Drp1 recruitment in mitochondrial fission.Mol Biol Cell 24: 659 – 667
Meeusen S, DeVay R, Block J, Cassidy-Stone A, Wayson S, McCaffery JM, Nunnari
J (2006) Mitochondrial inner-membrane fusion and crista maintenance
requires the dynamin-related GTPase Mgm1. Cell 127: 383 – 395
Miklos GL, Yamamoto M, Burns RG, Maleszka R (1997) An essential cell
division gene of Drosophila, absent from Saccharomyces, encodes an
unusual protein with tubulin-like and myosin-like peptide motifs. Proc
Natl Acad Sci USA 94: 5189 – 5194
Molnar MJ, Bencsik P (2006) Establishing a neurological-psychiatric biobank:
banking, informatics, ethics. Cell Immunol 244: 101 – 104
Mottier-Pavie V, Cenci G, Verni F, Gatti M, Bonaccorsi S (2011) Phenotypic
analysis of misato function reveals roles of noncentrosomal microtubules
in Drosophila spindle formation. J Cell Sci 124: 706 – 717
Nguyen TT, Oh SS, Weaver D, Lewandowska A, Maxfield D, Schuler MH, Smith
NK, Macfarlane J, Saunders G, Palmer CA et al (2014) Loss of Miro1-
directed mitochondrial movement results in a novel murine model for
neuron disease. Proc Natl Acad Sci USA 111: E3631 – E3640
Ono T, Isobe K, Nakada K, Hayashi JI (2001) Human cells are protected from
mitochondrial dysfunction by complementation of DNA products in fused
mitochondria. Nat Genet 28: 272 – 275
Otera H, Wang C, Cleland MM, Setoguchi K, Yokota S, Youle RJ, Mihara K (2010)
Mff is an essential factor for mitochondrial recruitment of Drp1 during
mitochondrial fission in mammalian cells. J Cell Biol 191: 1141 – 1158
Partikian A, Olveczky B, Swaminathan R, Li Y, Verkman AS (1998) Rapid
diffusion of green fluorescent protein in the mitochondrial matrix. J Cell
Biol 140: 821 – 829
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde
M, Lyon E, Spector E et al (2015) Standards and guidelines for the
interpretation of sequence variants: a joint consensus recommendation of
the American College of Medical Genetics and Genomics and the
Association for Molecular Pathology. Genet Med 17: 405 – 424
Song Z, Ghochani M, McCaffery JM, Frey TG, Chan DC (2009) Mitofusins and
OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol
Biol Cell 20: 3525 – 3532
Spiegel R, Saada A, Flannery PJ, Burte F, Soiferman D, Khayat M, Eisner V,
Vladovski E, Taylor RW, Bindoff LA et al (2016) Fatal infantile
mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and
optic atrophy associated with a homozygous OPA1 mutation. J Med Genet
53: 127 – 131
Suomalainen A (2015) Mitochondrial roles in disease: a box full of surprises.
EMBO Mol Med 7: 1245 – 1247
Twig G, Liu X, Liesa M, Wikstrom JD, Molina AJ, Las G, Yaniv G, Hajnoczky
G, Shirihai OS (2010) Biophysical properties of mitochondrial fusion
events in pancreatic beta-cells and cardiac cells unravel potential
control mechanisms of its selectivity. Am J Physiol Cell Physiol 299:
C477 –C487
Tyynismaa H, Ylikallio E, Patel M, Molnar MJ, Haller RG, Suomalainen A
(2009) A heterozygous truncating mutation in RRM2B causes autosomal-
dominant progressive external ophthalmoplegia with multiple mtDNA
deletions. Am J Hum Genet 85: 290 – 295
Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of
genetic variants from high-throughput sequencing data. Nucleic Acids Res
38: e164
Weaver D, Eisner V, Liu X, Varnai P, Hunyady L, Gross A, Hajnoczky G (2014)
Distribution and apoptotic function of outer membrane proteins depend
on mitochondrial fusion. Mol Cell 54: 870 – 878
Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino
H, Lee EF, Fairlie WD, Bouillet P et al (2007) Apoptosis initiated when BH3
ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315:
856 – 859
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
EMBO Molecular Medicine ª 2017 The Authors
EMBO Molecular Medicine Linking of MSTO1 to myopathy and ataxia Aniko Gal et al
18
Published online: May 29, 2017 
